DexCom Inc
Change company Symbol lookup
Select an option...
DXCM DexCom Inc
CSRLF CSR Ltd
LGIH LGI Homes Inc
ARI Apollo Commercial Real Estate Finance Inc
D Dominion Energy Inc
QTS-A QTS Realty Trust Inc
ICHR Ichor Holdings Ltd
AMRC Ameresco Inc
AVID Avid Technology Inc
NBIX Neurocrine Biosciences Inc
Go

Health Care : Health Care Equipment & Supplies | Large Cap Growth
Company profile

Dexcom, Inc. (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company's products consist of DexCom G4 PLATINUM and DexCom G5 Mobile. The Company is commercializing its fifth generation CGM system. The Company's markets DexCom G4 PLATINUM under a Conformite Europeenne Marking (CE Mark), in the European Union, Australia, New Zealand and the countries in Asia and Latin America, and in the United States with approval from the United States Food and Drug Administration (FDA). The DexCom G4 PLATINUM with Share remote monitoring system uses a wireless connection between a patient's receiver and an application on the patient's iPhone, iPod touch, or iPad to transmit glucose information to applications on the mobile devices of designated recipients (followers).

Closing Price
$443.67
Day's Change
8.13 (1.87%)
Bid
--
Ask
--
B/A Size
--
Day's High
449.45
Day's Low
432.39
Volume
(Average)
Volume:
845,467

10-day average volume:
867,934
845,467

Enlivex's stock rockets after plans to boost in capacity for treatment of COVID-19-like symptoms

8:18 am ET February 24, 2020 (MarketWatch)
Print

Shares of Israel-based Enlivex Therapeutics Ltd. (ENLV) rocketed 53% in active premarket trading Monday, after the clinical-stage immunotherapy company said it has started a plan to increase its manufacturing capacity of Allocetra, following the first confirmed case of COVID-19 in Israel. Trading volume rose to about 76,000 shares, compared with the full-day average of about 17,000 shares. Allocetra is being studied for the treat of patients with organ failure associated with sepsis, which the company said the lethal pathophysiology, which is cytokine storm followed by organ failure, is similar to that of COVID-19. The stock has run up 19.6% over the past three months through Friday, while the iShares Nasdaq Biotechnology ETF (IBB) has gained 6.7% and the S&P 500 has advanced 7.3%.

-Tomi Kilgore; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

February 24, 2020 08:18 ET (13:18 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.